Home Stock

Stock Research: Lotus Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Lotus Pharmaceutical

TAI:1795 TW0001795003
80
  • Value
    84
  • Growth
    83
  • Safety
    Safety
    8
  • Combined
    67
  • Sentiment
    78
  • 360° View
    360° View
    80
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Lotus Pharmaceutical Co Ltd is a Taiwan-based company focused on manufacturing and selling generic drugs, including solid preparations like tablets and capsules. The company operates in oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs, and mental disease drugs, and is also involved in drug research, development, clinical testing, and product licensing. Its main markets are Taiwan, South Korea, the United States, China mainland, Japan, Europe, and Southeast Asia. In the last fiscal year, the company had a market cap of $1963 million, profits of $333 million, and revenue of $567 million.

more

ANALYSIS: With an Obermatt 360° View of 80 (better than 80% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Lotus Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Lotus Pharmaceutical. The consolidated Value Rank has an attractive rank of 84, which means that the share price of Lotus Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 84% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 83, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 78. But the company’s financing is risky with a Safety rank of 8. This means 92% of comparable companies have a safer financing structure than Lotus Pharmaceutical. ...read more

more
Strongest Rank Leverage
Weakest Rank Dividend Yield
Country Taiwan
Industry Pharmaceuticals
Size Medium
Website lotuspharm.com.tw
Index
FTSE Taiwan
Lotus Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 17-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 38 38 65
Growth
83 80 87 85
Safety
Safety
8 13 18 18
Sentiment
78 100 90 69
360° View
360° View
80 69 70 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
18 93 91 95
Opinions Change
92 50 50 50
Pro Holdings
n/a 100 96 4
Market Pulse
88 100 46 79
Sentiment
78 100 90 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 38 38 65
Growth
83 80 87 85
Safety Safety
8 13 18 18
Combined
67 38 42 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
59 24 24 69
Price vs. Earnings (P/E)
68 74 65 91
Price vs. Book (P/B)
48 22 18 47
Dividend Yield
100 67 64 62
Value
84 38 38 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
96 84 82 67
Profit Growth
82 44 69 76
Capital Growth
5 55 51 25
Stock Returns
70 64 71 89
Growth
83 80 87 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
3 11 11 8
Refinancing
38 26 29 43
Liquidity
32 22 39 24
Safety Safety
8 13 18 18

Similar Stocks

Discover high‑ranked alternatives to Lotus Pharmaceutical and broaden your portfolio horizons.

Shimadzu

TYO:7701
Country: Japan
Industry: Electronic Equipment
Size: X-Large
Full Stock Analysis

Cosmo Energy Holdings

TYO:5021
Country: Japan
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

Phison Electronics

TWO:8299
Country: Taiwan
Industry: Semiconductors
Size: Medium
Full Stock Analysis

TOPCO Scientific

TAI:5434
Country: Taiwan
Industry: Semiconductor Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews